TY - JOUR A1 - Leutritz, Anna Linda A1 - van Braam, Lara A1 - Preis, Katharina A1 - Gehrmann, Andrea A1 - Scherf-Clavel, Maike A1 - Fiedler, Katrin A1 - Unterecker, Stefan A1 - Kittel-Schneider, Sarah T1 - Psychotropic medication in pregnancy and lactation and early development of exposed children JF - British Journal of Clinical Pharmacology N2 - There is still limited knowledge about alterations of blood concentrations of psychotropic drugs during pregnancy, the transfer of psychotropic drugs into breastmilk and the effects on exposed children. We investigated changes in concentrations of psychopharmacological medication during pregnancy and lactation in serum and breastmilk at different time points in a naturalistic sample of 60 mothers and observed the development of the exposed children in the first 12 months. We found a decrease in serum concentrations from the first to the second trimester of amitriptyline, duloxetine, escitalopram, quetiapine and sertraline. Citalopram stayed rather stable during pregnancy, sertraline levels interestingly increased again from the second to the third trimester. High concentration-by-dose ratios in breastmilk were found for venlafaxine as well as lamotrigine, low for quetiapine and clomipramine. Similarly, clomipramine and quetiapine showed low milk/serum–penetration ratios. Regarding the birth outcome measures in children, we found no significant differences between in utero exposed compared to nonexposed newborns. There were no significant differences in the development in the first 12 months. Psychotropic medication in the peripartum needs a balancing of risks and benefits and a continuous therapeutic drug monitoring can be a guidance for clinicians to monitor drug alteration patterns, which are likely to occur due to physiological pregnancy-associated changes in pharmacokinetics. Accordingly, therapeutic drug monitoring can optimize a medication in pregnancy and lactation with the lowest effective dose. KW - antidepressants KW - psychotropic medication KW - pregnancy KW - peripartum KW - mental disorders KW - lactation KW - child development Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-318954 VL - 89 IS - 2 SP - 737 EP - 750 ER - TY - THES A1 - Reber, Sibylle T1 - Einfluss von Multimorbidität und Niereninsuffizienz auf die Serumkonzentration von Antidepressiva sowie Assoziation zum Therapieergebnis bei einem Patientenkollektiv der Neurogerontopsychiatrischen Tagesklinik Würzburg T1 - Serum concentration of antidepressant drugs and therapy outcome in geriatric day care patients with renal insufficiency and multimorbidity N2 - Die vorliegende retrospektive Untersuchung arbeitete mit Daten von 153 Patienten der Neurogerontopsychiatrischen Tagesklinik Würzburg. Dabei wurde zum einen geprüft, ob multimorbide Patienten und niereninsuffiziente Patienten höhere dosiskorrigierte Serumkonzentrationen der Antidepressiva Escitalopram, Sertralin, Venlafaxin und Mirtazapin aufwiesen. Zum anderen erfolgte die Untersuchung, ob hohe Serumkonzentrationen der vier genannten Antidepressiva zu einem besseren Therapieergebnis führten. Für die Berechnungen wurden die letzten vor Entlassung erhobenen Laborparameter verwendet. Es erfolgte die Berechnung der dosiskorrigierten Serumkonzentration. 76 Patienten (49,7 %) wurden als multimorbide eingestuft. Es zeigten sich für die dosiskorrigierte Serumkonzentration des aktiven Metaboliten O-Desmethyl-Venlafaxin statistisch signifikant höhere Konzentrationen bei der multimorbiden Subgruppe. Ferner zeigte sich bei 140 Patienten eine Niereninsuffizienz (91,5 %). Für die dosiskorrigierte Konzentration von O-Desmethyl Venlafaxin, die dosiskorrigierte Summenserumkonzentration aus Venlafaxin und O-Desmethyl- Venlafaxin sowie die dosiskorrigierte Serumkonzentration von Sertralin ließen sich statistisch signifikant höhere Konzentrationen bei einer zunehmenden Einschränkung der Nierenfunktion nachweisen. Es zeigte sich kein Einfluss der Höhe der dosiskorrigierten Serumkonzentration der Antidepressiva auf das Therapieergebnis in der vorliegenden Arbeit. Mit der vorliegenden Arbeit konnte gezeigt werden, dass sowohl Multimorbidität als auch Niereninsuffizienz einen Einfluss auf die Verstoffwechselung und auch die dosiskorrigierte Serumkonzentration der Antidepressiva Venlafaxin und Sertralin haben. Daher ergibt sich die Schlussfolgerung, dass bei älteren Patienten, welche von Multimorbidität oder Niereninsuffizienz betroffen sind, eine Dosisanpassung und regelmäßige Kontrollen der Serumkonzentration im Sinne eines Therapeutischen Drug Monitoring erfolgen sollten. N2 - Geriatric patients are prone to develop chronic diseases. The geriatric depression is challenging considering the treatment due to age-related changes in pharmacokinetics and pharmacodynamics. Multimorbidity and renal function impairment are very common among old aged people. The present study aimed to examine the effect of chronic kidney disease and multimorbidity on the dose-corrected serum concentration of antidepressants. Moreover, the association between the serum concentration and the therapy outcome was evaluated. In the present retrospective, naturalistic study, data from 153 geriatric patients of a gerontopsychiatric day care unit of the University Hospital of Würzburg were analysed. In the present study, the dose-corrected serum concentration of the active metabolite O-desmethyl-venlafaxine was significantly higher in the multimorbid subgroup. The dose-corrected serum concentrations of O-desmethyl venlafaxine as well as for the dose-corrected total serum concentrations of venlafaxine and O-desmethyl Venlafaxine were significantly higher in patients with increasing impairment of kidney function. Also for sertraline higher dose-corected serum concentrations could be found with increasing impairment of renal function There was no influence of the level of the dose-corrected serum concentration of the Antidepressants on the outcome of the therapy in the present study. Due to higher dose-corrected serum concentrations in patients affected by renal insufficiency, multimorbidity venlafaxine should be administered more cautiously in these patients. Moreover, the doses of sertraline should be critically administered in patients with renal insufficiency. Further studies are needed in the future to assess the long-term effects of antidepressant therapy in geriatric patients. In addition, there is a need to evaluate other influences on the serum concentration of Antidepressants in the elderly. KW - Pharmakokinetik KW - Multimorbidität KW - Niereninsuffizienz KW - Altersdepression Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-321765 ER - TY - JOUR A1 - Gehrmann, Andrea A1 - Fiedler, Katrin A1 - Leutritz, Anna Linda A1 - Koreny, Carolin A1 - Kittel-Schneider, Sarah T1 - Lithium medication in pregnancy and breastfeeding — a case series JF - Medicina N2 - Lithium salts are the first-line prophylaxis treatment for bipolar disorder in most guidelines. The majority of bipolar women are treated with mood stabilizers at the time they wish to get pregnant. One reason for this is the rising average age at first childbirth, at least in the high-income countries, which increases in general the likelihood of a medication with psychotropic drugs. Previously, lithium exposition during pregnancy was thought to strongly increase the risk of severe cardiac malformation. However, recent studies only point to a low teratogenic risk, so nowadays an increasing number of women are getting pregnant with ongoing lithium treatment. Regarding lithium medication during breastfeeding, there is evidence that lithium transfers to the breastmilk and can also be detected in the infants' serum. The influence on the infant is still a largely understudied topic. Regular monitoring of the infants' renal clearance, thyroid function, and lithium levels is warranted when breastfeeding under lithium exposure. In this case series, we present three case reports of bipolar mothers who were treated with lithium during pregnancy and breastfeeding to add to the scarce literature on this important topic. In short, we strengthen the importance of therapeutic drug monitoring due to fluctuating plasma levels during pregnancy and after birth, and we can report the birth and development of three healthy infants despite lithium medication during pregnancy and breastfeeding. KW - lithium KW - pregnancy KW - lactation Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-285640 SN - 1648-9144 VL - 57 IS - 6 ER - TY - THES A1 - Müller, Annika Wiebke T1 - Funktionalität eines \(Stathmin\)-Promotor-Polymorphismus T1 - Functionality of a \(stathmin\) promoter polymorphism N2 - Bereits in vorausgegangenen Studien konnte nachgewiesen werden, dass das Stathmin-Gen eine entscheidende Rolle im Hinblick auf erlernte und angeborene Angstreaktionen spielt. So konnte Frau Dr. Julia Katharina Heupel in ihrer Arbeit aus dem Jahr 2013 eine Assoziation eines (TAA)n-Polymorphismus, welcher sich ca. 2 kb upstream des ersten Exons des Stathmin-Gens und ca. 4 kb upstream des Translationsstarts befindet, mit Cluster-C-Persönlichkeitsstörungen belegen. Sie vermutete, dass eine Hochregulation der Expression des Stathmin-Gens ein Risikofaktor für die Entstehung von Cluster C Persönlichkeitsstörungen darstellen könnte. Da sich der beschriebene Polymorphismus in der Promotor-Region des Stathmin-Gens befindet, ist eine allelspezifische Auswirkung auf die Genexpression vorstellbar. Um diese Vermutung zu stützen, wurde in dieser Arbeit die Auswirkung zweier Allele des STR-Polymorphismus im Bereich der Promotorregion des Stathmin-Gens im Hinblick auf die Promotoraktivität untersucht. Hierzu wurde die zu untersuchende Sequenz zunächst mittels Polymerase-Ketten-Reaktion vervielfältigt und anschließend in einen pGL4.23.Vektor kloniert. Im Anschluss daran erfolgte die Untersuchung der Promotoraktivität mittels eines Luciferase-Assays in der humanen Neuroblastomzelllinie SH-SY5Y. Nach statischer Auswertung der Messreihen zeigte sich eine signifikant höhere Luciferase-Aktivität des STR-Polymorphismus (TAA)12 im Vergleich zu dem STR-Polymorphismus (TAA)13. Hierdurch kann von einer höheren Promotoraktivität bei dem Genotyp (TAA)12 gegenüber dem Genotyp (TAA)13 ausgegangen werden. Zusammenfassend unterstützen die Ergebnisse dieser Arbeit die These, dass es sich bei dem Stathmin-Gen um ein Suszeptibilitätsgen für die Entstehung von Cluster C Persönlichkeitsstörungen handeln könnte. N2 - Previous studies have shown that the stathmin gene plays a crucial role in both learned and innate fear. In 2013 Dr. Julia Katharina Heupel suggested an association between a (TAA)n-polymorphism - which is located around 2 kb upstream of the first exon of the stathmin gene and around 4 kb upstream of the translation start site – with Cluster C personality disorders. She assumed that the upregulation of the stathmin gene expression constitutes a risk factor for the development of Cluster C personality disorders. Since the polymorphism described is located in the promoter region of the stathmin gene, an allele-specific effect on gene expression is conceivable. To support this premise, the impact on promoter activity of two alleles of the STR polymorphism located in the promoter region of the stathmin gene was investigated. First the sequence was amplified using polymerase chain reaction and then cloned into a pGL4.23 vector. Subsequently, the promoter activity was analyzed using a luciferase assay in the human neuroblastoma cell line SH-SY5Y. After statistical evaluation a significantly higher luciferase activity of the STR polymorphism (TAA)12 was shown in comparison to the STR polymorphism (TAA)13. As a result, it can be assumed that the genotype (TAA)12 has a higher promoter activity than the genotype (TAA)13. In summary, the results of this work support the thesis that the stathmin gene could be a susceptibility gene for the development of Cluster C personality disorders. KW - Persönlichkeitsstörung KW - Stathmin KW - Cluster C Persönlichkeitsstörungen KW - Promotorpolymorphismus KW - Cluster C personality disorders KW - promoter polymorphism Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-318120 ER - TY - THES A1 - Gründahl, Marthe Erda T1 - From Lab to Life: Investigating the Role of Social Contact for Anxiety and Related Autonomic Responses T1 - Vom Labor ins Leben: Die Erforschung der Rolle von sozialem Kontakt für Angst und damit verbundene autonome Reaktionen N2 - Social contact is an integral part of daily life. Its health-enhancing effects include reduced negative affective experiences of fear and anxiety, a phenomenon called social buffering. This dissertation studied different forms of social contact and their anxiety-buffering effects with diverse methodologies. The laboratory-based first study investigated minimal social contact in the context of pain relief learning. Results showed that the observed decreased autonomic and increased subjective fear responses following pain relief learning were independent of social influence. The minimalistic and controlled social setting may have prevented social buffering. Study 2 targeted social buffering in daily life using Ecological Momentary Assessment. We repeatedly assessed individuals’ state anxiety, related cardiovascular responses, and aspects of social interactions with smartphones and portable sensors on five days. Analyses of over 1,500 social contacts revealed gender-specific effects, e.g., heart rate-reducing effects of familiarity in women, but not men. Study 3 examined anxiety, loneliness, and related social factors in the absence of social contact due to social distancing. We constructed and validated a scale measuring state and trait loneliness and isolation, and analysed its link to mental health. Results include a social buffering-like relation of lower anxiety with more trait sociability and sense of belonging. In sum, the studies showed no fear reduction by minimal social contact, but buffering effects relating to social and personal factors in more complex social situations. Anxiety responses during daily social contacts were lower with more familiar or opposite-gender interaction partners. During limited social contact, lower anxiety related to inter-individual differences in sociability, social belonging, and loneliness. By taking research from lab to life, this dissertation underlined the diverse nature of social contact and its relevance to mental health. N2 - Sozialer Kontakt ist ein wesentlicher Teil des Alltags. Zu seinen Effekten gehört die Minderung negativer affektiver Erfahrungen von Angst und Furcht („Social Buffering“). Diese Dissertation untersucht verschiedene Formen sozialen Kontakts und ihre angstmindernde Wirkung mit diversen Methoden. Studie 1 untersuchte minimalen sozialen Kontakt im Kontext von Pain Relief Learning im Labor. Die verringerten autonomen und erhöhten subjektiven Furchtreaktionen nach dem Pain Relief Learning waren unabhängig vom sozialen Einfluss. Das minimalistische und kontrollierte soziale Setting könnte Social Buffering verhindert haben. Studie 2 erfasste Social Buffering im Alltag mit Ecological Momentary Assessment. An fünf Tagen wurden wiederholt State Angst und kardiovaskuläre Reaktionen der ProbandInnen sowie Merkmale ihrer sozialen Interaktionen mit Smartphones und tragbaren Sensoren gemessen. Die Analyse der über 1500 sozialen Kontakte ergab geschlechtsspezifische Effekte, z. B. eine herzratenmindernde Wirkung von Vertrautheit bei Frauen, aber nicht bei Männern. Studie 3 untersuchte Angst, Einsamkeit und weitere soziale Faktoren bei abwesendem sozialen Kontakt durch Social Distancing. Wir konstruierten und validierten eine Skala zur Messung von State- und Trait-Einsamkeit und Isolation und prüften ihren Zusammenhang mit psychischer Gesundheit. Weniger Angst ging mit mehr Trait-Geselligkeit und Zugehörigkeitsgefühl einher. Somit zeigte sich keine Furchtminderung bei minimalem sozialen Kontakt, aber Social Buffering in komplexeren sozialen Situationen bedingt durch soziale und persönliche Faktoren. Angstreaktionen waren in Alltagsinteraktionen mit vertrauteren oder gegengeschlechtlichen Personen geringer. Bei begrenztem sozialen Kontakt ging geringere Angst mit Unterschieden in Geselligkeit, sozialer Zugehörigkeit und Einsamkeit einher. Durch Forschung in Labor und Leben unterstreicht diese Dissertation die Vielfältigkeit sozialer Kontakte und ihre Relevanz für psychische Gesundheit. KW - Angst KW - Sozialer Kontakt KW - Herzfrequenz KW - Angst als Zustand KW - Einsamkeit KW - Social Buffering KW - Ecological Momentary Assessment KW - Hautleitfähigkeit KW - Social Distancing Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-316859 ER - TY - JOUR A1 - Hibar, Derrek P. A1 - Adams, Hieab H.H. A1 - Jahanshad, Neda A1 - Chauhan, Ganesh A1 - Stein, Jason L A1 - Hofer, Edith A1 - Renteria, Miguel E. A1 - Bis, Joshua C. A1 - Arias-Vasquez, Alejandro A1 - Ikram, M. Kamran A1 - Desrivières, Sylvane A1 - Vernooij, Meike W. A1 - Abramovic, Lucija A1 - Alhusaini, Saud A1 - Amin, Najaf A1 - Andersson, Micael A1 - Arfanakis, Konstantinos A1 - Aribisala, Benjamin S. A1 - Armstrong, Nicola J. A1 - Athanasiu, Lavinia A1 - Axelsson, Tomas A1 - Beecham, Ashley H. A1 - Beiser, Alexa A1 - Bernard, Manon A1 - Blanton, Susan H. A1 - Bohlken, Marc M. A1 - Boks, Marco P. A1 - Bralten, Janita A1 - Brickman, Adam M. A1 - Carmichael, Owen T1 - Novel genetic loci associated with hippocampal volume JF - Nature Communications N2 - The hippocampal formation is a brain structure integrally involved in episodic memory, spatial navigation, cognition and stress responsiveness. Structural abnormalities in hippocampal volume and shape are found in several common neuropsychiatric disorders. To identify the genetic underpinnings of hippocampal structure here we perform a genome-wide association study (GWAS) of 33,536 individuals and discover six independent loci significantly associated with hippocampal volume, four of them novel. Of the novel loci, three lie within genes (ASTN2, DPP4 and MAST4) and one is found 200 kb upstream of SHH. A hippocampal subfield analysis shows that a locus within the MSRB3 gene shows evidence of a localized effect along the dentate gyrus, subiculum, CA1 and fissure. Further, we show that genetic variants associated with decreased hippocampal volume are also associated with increased risk for Alzheimer’s disease (r\(_g\)=−0.155). Our findings suggest novel biological pathways through which human genetic variation influences hippocampal volume and risk for neuropsychiatric illness. KW - brain KW - hippocampal formation KW - neuropsychiatric disorders KW - Alzheimer’s disease KW - genetic loci KW - hippocampal volume Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-182115 VL - 8 ER - TY - JOUR A1 - Vangeel, Elise Beau A1 - Pishva, Ehsan A1 - Hompes, Titia A1 - van den Hove, Daniel A1 - Lambrechts, Diether A1 - Allegaert, Karel A1 - Freson, Kathleen A1 - Izzi, Benedetta A1 - Claes, Stephan T1 - Newborn genome-wide DNA methylation in association with pregnancy anxiety reveals a potential role for \(GABBR1\) JF - Clinical Epigenetics N2 - Background: There is increasing evidence for the role of prenatal stress in shaping offspring DNA methylation and disease susceptibility. In the current study, we aimed to identify genes and pathways associated with pregnancy anxiety using a genome-wide DNA methylation approach. Methods: We selected 22 versus 23 newborns from our Prenatal Early Life Stress (PELS) cohort, exposed to the lowest or highest degree of maternal pregnancy anxiety, respectively. Cord blood genome-wide DNA methylation was assayed using the HumanMethylation450 BeadChip (HM450, n = 45) and candidate gene methylation using EpiTYPER (n = 80). Cortisol levels were measured at 2, 4, and 12 months of age to test infant stress system (re)activity. Results: Data showed ten differentially methylated regions (DMR) when comparing newborns exposed to low versus high pregnancy anxiety scores. We validated a top DMR in the GABA-B receptor subunit 1 gene (GABBR1) revealing the association with pregnancy anxiety particularly in male newborns (most significant CpG Pearson R = 0.517, p = 0.002; average methylation Pearson R = 0.332, p = 0.039). Cord blood GABBR1 methylation was associated with infant cortisol levels in response to a routine vaccination at 4 months old. Conclusions: In conclusion, our results show that pregnancy anxiety is associated with differential DNA methylation patterns in newborns and that our candidate gene GABBR1 is associated with infant hypothalamic-pituitary-adrenal axis response to a stressor. Our findings reveal a potential role for GABBR1 methylation in association with stress and provide grounds for further research. KW - DNA methylation KW - GABBR1 KW - gender differences KW - HPA axis KW - pregnancy anxiety KW - prenatal stress Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-173825 VL - 9 ER - TY - JOUR A1 - Buff, Christine A1 - Brinkmann, Leonie A1 - Bruchmann, Maximilian A1 - Becker, Michael P.I. A1 - Tupak, Sara A1 - Herrmann, Martin J. A1 - Straube, Thomas T1 - Activity alterations in the bed nucleus of the stria terminalis and amygdala during threat anticipation in generalized anxiety disorder JF - Social Cognitive and Affective Neuroscience N2 - Sustained anticipatory anxiety is central to Generalized Anxiety Disorder (GAD). During anticipatory anxiety, phasic threat responding appears to be mediated by the amygdala, while sustained threat responding seems related to the bed nucleus of the stria terminalis (BNST). Although sustained anticipatory anxiety in GAD patients was proposed to be associated with BNST activity alterations, firm evidence is lacking. We aimed to explore temporal characteristics of BNST and amygdala activity during threat anticipation in GAD patients. Nineteen GAD patients and nineteen healthy controls (HC) underwent functional magnetic resonance imaging (fMRI) during a temporally unpredictable threat anticipation paradigm. We defined phasic and a systematic variation of sustained response models for blood oxygen level-dependent responses during threat anticipation, to disentangle temporally dissociable involvement of the BNST and the amygdala. GAD patients relative to HC responded with increased phasic amygdala activity to onset of threat anticipation and with elevated sustained BNST activity that was delayed relative to the onset of threat anticipation. Both the amygdala and the BNST displayed altered responses during threat anticipation in GAD patients, albeit with different time courses. The results for the BNST activation hint towards its role in sustained threat responding, and contribute to a deeper understanding of pathological sustained anticipatory anxiety in GAD. KW - medicine KW - anticipatory anxiety KW - anxiety KW - fMRI KW - sustained threat responding KW - phasic threat responding Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-173298 VL - 12 IS - 11 ER - TY - JOUR A1 - Janson, Patrick A1 - Willeke, Kristina A1 - Zaibert, Lisa A1 - Budnick, Andrea A1 - Berghöfer, Anne A1 - Kittel-Schneider, Sarah A1 - Heuschmann, Peter U. A1 - Zapf, Andreas A1 - Wildner, Manfred A1 - Stupp, Carolin A1 - Keil, Thomas T1 - Mortality, morbidity and health-related outcomes in informal caregivers compared to non-caregivers: a systematic review JF - International Journal of Environmental Research and Public Health N2 - A systematic overview of mental and physical disorders of informal caregivers based on population-based studies with good methodological quality is lacking. Therefore, our aim was to systematically summarize mortality, incidence, and prevalence estimates of chronic diseases in informal caregivers compared to non-caregivers. Following PRISMA recommendations, we searched major healthcare databases (CINAHL, MEDLINE and Web of Science) systematically for relevant studies published in the last 10 years (without language restrictions) (PROSPERO registration number: CRD42020200314). We included only observational cross-sectional and cohort studies with low risk of bias (risk scores 0–2 out of max 8) that reported the prevalence, incidence, odds ratio (OR), hazard ratio (HR), mean- or sum-scores for health-related outcomes in informal caregivers and non-caregivers. For a thorough methodological quality assessment, we used a validated checklist. The synthesis of the results was conducted by grouping outcomes. We included 22 studies, which came predominately from the USA and Europe. Informal caregivers had a significantly lower mortality than non-caregivers. Regarding chronic morbidity outcomes, the results from a large longitudinal German health-insurance evaluation showed increased and statistically significant incidences of severe stress, adjustment disorders, depression, diseases of the spine and pain conditions among informal caregivers compared to non-caregivers. In cross-sectional evaluations, informal caregiving seemed to be associated with a higher occurrence of depression and of anxiety (ranging from 4 to 51% and 2 to 38%, respectively), pain, hypertension, diabetes and reduced quality of life. Results from our systematic review suggest that informal caregiving may be associated with several mental and physical disorders. However, these results need to be interpreted with caution, as the cross-sectional studies cannot determine temporal relationships. The lower mortality rates compared to non-caregivers may be due to a healthy-carer bias in longitudinal observational studies; however, these and other potential benefits of informal caregiving deserve further attention by researchers. KW - cohort studies KW - longitudinal studies KW - cross-sectional studies KW - family caregivers KW - informal caregiving KW - mental health KW - physical health KW - population-based studies KW - systematic review Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-275219 SN - 1660-4601 VL - 19 IS - 10 ER - TY - JOUR A1 - Strilciuc, Stefan A1 - Vécsei, László A1 - Boering, Dana A1 - Pražnikar, Aleš A1 - Kaut, Oliver A1 - Riederer, Peter A1 - Battistin, Leontino T1 - Safety of Cerebrolysin for neurorecovery after acute ischemic stroke: a systematic review and meta-analysis of twelve randomized-controlled trials JF - Pharmaceuticals N2 - We performed a systematic search and meta-analysis of available literature to determine the safety profile of Cerebrolysin in acute ischemic stroke, filling existing safety information gaps and inconsistent results. We searched EMBASE, PubMed, and Cochrane Databases of Systematic Reviews and Clinical Trials up to the end of February 2021. Data collection and analysis were conducted using methods described in the Cochrane Handbook for Systematic Reviews of Interventions. All safety outcomes were analyzed based on risk ratios (RR) and their 95% confidence intervals. The meta-analysis pooled 2202 patients from twelve randomized clinical trials, registering non-statistically significant (p > 0.05) differences between Cerebrolysin and placebo throughout main and subgroup analyses. The lowest rate of Serious Adverse Events (SAE), as compared to placebo, was observed for the highest dose of Cerebrolysin (50 mL), highlighting a moderate reduction (RR = 0.6). We observed a tendency of superiority of Cerebrolysin regarding SAE in high dose treatment courses for moderate-severe ischemic stroke, suggesting some effect of the agent against adverse events. This comprehensive safety meta-analysis confirms the safety profile for patients treated with Cerebrolysin after acute ischemic stroke, as compared to placebo. KW - ischemic stroke KW - safety KW - Cerebrolysin KW - neurorehabilitation Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-252403 SN - 1424-8247 VL - 14 IS - 12 ER - TY - JOUR A1 - Dischinger, Ulrich A1 - Heckel, Tobias A1 - Bischler, Thorsten A1 - Hasinger, Julia A1 - Königsrainer, Malina A1 - Schmitt-Böhrer, Angelika A1 - Otto, Christoph A1 - Fassnacht, Martin A1 - Seyfried, Florian A1 - Hankir, Mohammed Khair T1 - Roux-en-Y gastric bypass and caloric restriction but not gut hormone-based treatments profoundly impact the hypothalamic transcriptome in obese rats JF - Nutrients N2 - Background: The hypothalamus is an important brain region for the regulation of energy balance. Roux-en-Y gastric bypass (RYGB) surgery and gut hormone-based treatments are known to reduce body weight, but their effects on hypothalamic gene expression and signaling pathways are poorly studied. Methods: Diet-induced obese male Wistar rats were randomized into the following groups: RYGB, sham operation, sham + body weight-matched (BWM) to the RYGB group, osmotic minipump delivering PYY3-36 (0.1 mg/kg/day), liraglutide s.c. (0.4 mg/kg/day), PYY3-36 + liraglutide, and saline. All groups (except BWM) were kept on a free choice of high- and low-fat diets. Four weeks after interventions, hypothalami were collected for RNA sequencing. Results: While rats in the RYGB, BWM, and PYY3-36 + liraglutide groups had comparable reductions in body weight, only RYGB and BWM treatment had a major impact on hypothalamic gene expression. In these groups, hypothalamic leptin receptor expression as well as the JAK–STAT, PI3K-Akt, and AMPK signaling pathways were upregulated. No significant changes could be detected in PYY3-36 + liraglutide-, liraglutide-, and PYY-treated groups. Conclusions: Despite causing similar body weight changes compared to RYGB and BWM, PYY3-36 + liraglutide treatment does not impact hypothalamic gene expression. Whether this striking difference is favorable or unfavorable to metabolic health in the long term requires further investigation. KW - obesity KW - Roux-en-Y gastric bypass surgery KW - liraglutide KW - PYY3-36 KW - hypothalamic gene expression Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-252392 SN - 2072-6643 VL - 14 IS - 1 ER - TY - JOUR A1 - Fernàndez-Castillo, Noèlia A1 - Cabana-Domínguez, Judit A1 - Kappel, Djenifer B. A1 - Torrico, Bàrbara A1 - Weber, Heike A1 - Lesch, Klaus-Peter A1 - Lao, Oscar A1 - Reif, Andreas A1 - Cormand, Bru T1 - Exploring the contribution to ADHD of genes involved in Mendelian disorders presenting with hyperactivity and/or inattention JF - Genes N2 - Attention-deficit hyperactivity disorder (ADHD) is a complex neurodevelopmental disorder characterized by hyperactivity, impulsivity, and/or inattention, which are symptoms also observed in many rare genetic disorders. We searched for genes involved in Mendelian disorders presenting with ADHD symptoms in the Online Mendelian Inheritance in Man (OMIM) database, to curate a list of new candidate risk genes for ADHD. We explored the enrichment of functions and pathways in this gene list, and tested whether rare or common variants in these genes are associated with ADHD or with its comorbidities. We identified 139 genes, causal for 137 rare disorders, mainly related to neurodevelopmental and brain function. Most of these Mendelian disorders also present with other psychiatric traits that are often comorbid with ADHD. Using whole exome sequencing (WES) data from 668 ADHD cases, we found rare variants associated with the dimension of the severity of inattention symptoms in three genes: KIF11, WAC, and CRBN. Then, we focused on common variants and identified six genes associated with ADHD (in 19,099 cases and 34,194 controls): MANBA, UQCC2, HIVEP2, FOPX1, KANSL1, and AUH. Furthermore, HIVEP2, FOXP1, and KANSL1 were nominally associated with autism spectrum disorder (ASD) (18,382 cases and 27,969 controls), as well as HIVEP2 with anxiety (7016 cases and 14,475 controls), and FOXP1 with aggression (18,988 individuals), which is in line with the symptomatology of the rare disorders they are responsible for. In conclusion, inspecting Mendelian disorders and the genes responsible for them constitutes a valuable approach for identifying new risk genes and the mechanisms of complex disorders. KW - ADHD KW - rare mendelian disorders KW - genetic variants Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-252346 SN - 2073-4425 VL - 13 IS - 1 ER - TY - JOUR A1 - Stein, Kiera A1 - Maruf, Abdullah Al A1 - Müller, Daniel J. A1 - Bishop, Jeffrey R. A1 - Bousman, Chad A. T1 - Serotonin transporter genetic variation and antidepressant response and tolerability: a systematic review and meta-analysis JF - Journal of Personalized Medicine N2 - Antidepressants are used to treat several psychiatric disorders; however, a large proportion of patients do not respond to their first antidepressant therapy and often experience adverse drug reactions (ADR). A common insertion–deletion polymorphism in the promoter region (5-HTTLPR) of the serotonin transporter (SLC6A4) gene has been frequently investigated for its association with antidepressant outcomes. Here, we performed a systematic review and meta-analysis to assess 5-HTTLPR associations with antidepressants: (1) response in psychiatric disorders other than major depressive disorder (MDD) and (2) tolerability across all psychiatric disorders. Literature searches were performed up to January 2021, yielding 82 studies that met inclusion criteria, and 16 of these studies were included in the meta-analyses. Carriers of the 5-HTTLPR LL or LS genotypes were more likely to respond to antidepressant therapy, compared to the SS carriers in the total and European ancestry-only study populations. Long (L) allele carriers taking selective serotonin reuptake inhibitors (SSRIs) reported fewer ADRs relative to short/short (SS) carriers. European L carriers taking SSRIs had lower ADR rates than S carriers. These results suggest the 5-HTTLPR polymorphism may serve as a marker for antidepressant outcomes in psychiatric disorders and may be particularly relevant to SSRI treatment among individuals of European descent. KW - 5-HTTLPR KW - genotype KW - pharmacogenetics KW - antidepressant KW - efficacy KW - tolerability KW - SLC6A4 Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-252294 SN - 2075-4426 VL - 11 IS - 12 ER - TY - JOUR A1 - Brunkhorst-Kanaan, Nathalie A1 - Trautmann, Sandra A1 - Schreiber, Yannick A1 - Thomas, Dominique A1 - Kittel-Schneider, Sarah A1 - Gurke, Robert A1 - Geisslinger, Gerd A1 - Reif, Andreas A1 - Tegeder, Irmgard T1 - Sphingolipid and endocannabinoid profiles in adult attention deficit hyperactivity disorder JF - Biomedicines N2 - Genes encoding endocannabinoid and sphingolipid metabolism pathways were suggested to contribute to the genetic risk towards attention deficit hyperactivity disorder (ADHD). The present pilot study assessed plasma concentrations of candidate endocannabinoids, sphingolipids and ceramides in individuals with adult ADHD in comparison with healthy controls and patients with affective disorders. Targeted lipid analyses of 23 different lipid species were performed in 71 mental disorder patients and 98 healthy controls (HC). The patients were diagnosed with adult ADHD (n = 12), affective disorder (major depression, MD n = 16 or bipolar disorder, BD n = 6) or adult ADHD with comorbid affective disorders (n = 37). Canonical discriminant analysis and CHAID analyses were used to identify major components that predicted the diagnostic group. ADHD patients had increased plasma concentrations of sphingosine-1-phosphate (S1P d18:1) and sphinganine-1-phosphate (S1P d18:0). In addition, the endocannabinoids, anandamide (AEA) and arachidonoylglycerol were increased. MD/BD patients had increased long chain ceramides, most prominently Cer22:0, but low endocannabinoids in contrast to ADHD patients. Patients with ADHD and comorbid affective disorders displayed increased S1P d18:1 and increased Cer22:0, but the individual lipid levels were lower than in the non-comorbid disorders. Sphingolipid profiles differ between patients suffering from ADHD and affective disorders, with overlapping patterns in comorbid patients. The S1P d18:1 to Cer22:0 ratio may constitute a diagnostic or prognostic tool. KW - attention deficit hyperactivity disorder KW - endocannabinoids KW - ceramides KW - bipolar disorder KW - major depression KW - tandem mass spectrometry Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-246080 SN - 2227-9059 VL - 9 IS - 9 ER - TY - JOUR A1 - Willeke, Kristina A1 - Janson, Patrick A1 - Zink, Katharina A1 - Stupp, Carolin A1 - Kittel-Schneider, Sarah A1 - Berghöfer, Anne A1 - Ewert, Thomas A1 - King, Ryan A1 - Heuschmann, Peter U. A1 - Zapf, Andreas A1 - Wildner, Manfred A1 - Keil, Thomas T1 - Occurrence of mental illness and mental health risks among the self-employed: a systematic review JF - International Journal of Environmental Research and Public Health N2 - We aimed to systematically identify and evaluate all studies of good quality that compared the occurrence of mental disorders in the self-employed versus employees. Adhering to the Cochrane guidelines, we conducted a systematic review and searched three major medical databases (MEDLINE, Web of Science, Embase), complemented by hand search. We included 26 (three longitudinal and 23 cross-sectional) population-based studies of good quality (using a validated quality assessment tool), with data from 3,128,877 participants in total. The longest of these studies, a Swedish national register evaluation with 25 years follow-up, showed a higher incidence of mental illness among the self-employed compared to white-collar workers, but a lower incidence compared to blue-collar workers. In the second longitudinal study from Sweden the self-employed had a lower incidence of mental illness compared to both blue- and white-collar workers over 15 years, whereas the third longitudinal study (South Korea) did not find a difference regarding the incidence of depressive symptoms over 6 years. Results from the cross-sectional studies showed associations between self-employment and poor general mental health and stress, but were inconsistent regarding other mental outcomes. Most studies from South Korea found a higher prevalence of mental disorders among the self-employed compared to employees, whereas the results of cross-sectional studies from outside Asia were less consistent. In conclusion, we found evidence from population-based studies for a link between self-employment and increased risk of mental illness. Further longitudinal studies are needed examining the potential risk for the development of mental disorders in specific subtypes of the self-employed. KW - incidence KW - mental disorders KW - mental health KW - mental illness KW - prevalence KW - self-employed KW - small business KW - systematic review Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-245085 SN - 1660-4601 VL - 18 IS - 16 ER - TY - JOUR A1 - Üçeyler, Nurcan A1 - Schließer, Mira A1 - Evdokimov, Dimitar A1 - Radziwon, Jakub A1 - Feulner, Betty A1 - Unterecker, Stefan A1 - Rimmele, Florian A1 - Walter, Uwe T1 - Reduced midbrain raphe echogenicity in patients with fibromyalgia syndrome JF - PloS One N2 - Objectives The pathogenesis of fibromyalgia syndrome (FMS) is unclear. Transcranial ultrasonography revealed anechoic alteration of midbrain raphe in depression and anxiety disorders, suggesting affection of the central serotonergic system. Here, we assessed midbrain raphe echogenicity in FMS. Methods Sixty-six patients underwent transcranial sonography, of whom 53 were patients with FMS (27 women, 26 men), 13 patients with major depression and physical pain (all women), and 14 healthy controls (11 women, 3 men). Raphe echogenicity was graded visually as normal or hypoechogenic, and quantified by digitized image analysis, each by investigators blinded to the clinical diagnosis. Results Quantitative midbrain raphe echogenicity was lower in patients with FMS compared to healthy controls (p<0.05), but not different from that of patients with depression and accompanying physical pain. Pain and FMS symptom burden did not correlate with midbrain raphe echogenicity as well as the presence and severity of depressive symptoms. Conclusion We found reduced echogenicity of the midbrain raphe area in patients with FMS and in patients with depression and physical pain, independent of the presence or severity of pain, FMS, and depressive symptoms. Further exploration of this sonographic finding is necessary before this objective technique may enter diagnostic algorithms in FMS and depression. KW - midbrain KW - fibromyalgia KW - depression KW - pain KW - ultrasound imaging KW - neuropathic pain KW - diagnostic medicine KW - migraine Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-300639 VL - 17 IS - 11 ER - TY - JOUR A1 - Kittel-Schneider, Sarah A1 - Felice, Ethel A1 - Buhagiar, Rachel A1 - Lambregtse-van den Berg, Mijke A1 - Wilson, Claire A. A1 - Banjac Baljak, Visnja A1 - Vujovic, Katarina Savic A1 - Medic, Branislava A1 - Opankovic, Ana A1 - Fonseca, Ana A1 - Lupattelli, Angela T1 - Treatment of peripartum depression with antidepressants and other psychotropic medications: a synthesis of clinical practice guidelines in Europe JF - International Journal of Environmental Research and Public Health N2 - This study examined (1) the availability and content of national CPGs for treatment of peripartum depression, including comorbid anxiety, with antidepressants and other psychotropics across Europe and (2) antidepressant and other psychotropic utilization data as an indicator of prescribers' compliance to the guidelines. We conducted a search using Medline and the Guidelines International Network database, combined with direct e-mail contact with national Riseup-PPD COST ACTION members and researchers within psychiatry. Of the 48 European countries examined, we screened 41 records and included 14 of them for full-text evaluation. After exclusion of ineligible and duplicate records, we included 12 CPGs. Multiple CPGs recommend antidepressant initiation or continuation based on maternal disease severity, non-response to first-line non-pharmacological interventions, and after risk-benefit assessment. Advice on treatment of comorbid anxiety is largely missing or unspecific. Antidepressant dispensing data suggest general prescribers' compliance with the preferred substances of the CPG, although country-specific differences were noted. To conclude, there is an urgent need for harmonized, up-to-date CPGs for pharmacological management of peripartum depression and comorbid anxiety in Europe. The recommendations need to be informed by the latest available evidence so that healthcare providers and women can make informed, evidence-based decisions about treatment choices. KW - clinical practice guideline KW - depression KW - anxiety KW - antidepressant KW - psychotropic medications KW - peripartum Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-262130 SN - 1660-4601 VL - 19 IS - 4 ER - TY - JOUR A1 - Lichter, Katharina A1 - Paul, Mila Marie A1 - Pauli, Martin A1 - Schoch, Susanne A1 - Kollmannsberger, Philip A1 - Stigloher, Christian A1 - Heckmann, Manfred A1 - Sirén, Anna-Leena T1 - Ultrastructural analysis of wild-type and RIM1α knockout active zones in a large cortical synapse JF - Cell Reports N2 - Rab3A-interacting molecule (RIM) is crucial for fast Ca\(^{2+}\)-triggered synaptic vesicle (SV) release in presynaptic active zones (AZs). We investigated hippocampal giant mossy fiber bouton (MFB) AZ architecture in 3D using electron tomography of rapid cryo-immobilized acute brain slices in RIM1α\(^{−/−}\) and wild-type mice. In RIM1α\(^{−/−}\), AZs are larger with increased synaptic cleft widths and a 3-fold reduced number of tightly docked SVs (0–2 nm). The distance of tightly docked SVs to the AZ center is increased from 110 to 195 nm, and the width of their electron-dense material between outer SV membrane and AZ membrane is reduced. Furthermore, the SV pool in RIM1α\(^{−/−}\) is more heterogeneous. Thus, RIM1α, besides its role in tight SV docking, is crucial for synaptic architecture and vesicle pool organization in MFBs. KW - active zone KW - acute brain slices KW - CA3 KW - electron tomography KW - high-pressure freezing KW - hippocampal mossy fiber bouton KW - RIM1α KW - SV pool KW - synaptic ultrastructure KW - presynaptic Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-300913 VL - 40 IS - 12 ER - TY - JOUR A1 - Traub, Jan A1 - Otto, Markus A1 - Sell, Roxane A1 - Göpfert, Dennis A1 - Homola, György A1 - Steinacker, Petra A1 - Oeckl, Patrick A1 - Morbach, Caroline A1 - Frantz, Stefan A1 - Pham, Mirko A1 - Störk, Stefan A1 - Stoll, Guido A1 - Frey, Anna T1 - Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients JF - Alzheimer's Research & Therapy N2 - Background Chronic heart failure (HF) is known to increase the risk of developing Alzheimer’s dementia significantly. Thus, detecting and preventing mild cognitive impairment, which is common in patients with HF, is of great importance. Serum biomarkers are increasingly used in neurological disorders for diagnostics, monitoring, and prognostication of disease course. It remains unclear if neuronal biomarkers may help detect cognitive impairment in this high-risk population. Also, the influence of chronic HF and concomitant renal dysfunction on these biomarkers is not well understood. Methods Within the monocentric Cognition.Matters-HF study, we quantified the serum levels of phosphorylated tau protein 181 (pTau) and neurofilament light chain (NfL) of 146 extensively phenotyped chronic heart failure patients (aged 32 to 85 years; 15.1% women) using ultrasensitive bead-based single-molecule immunoassays. The clinical work-up included advanced cognitive testing and cerebral magnetic resonance imaging (MRI). Results Serum concentrations of NfL ranged from 5.4 to 215.0 pg/ml (median 26.4 pg/ml) and of pTau from 0.51 to 9.22 pg/ml (median 1.57 pg/ml). We detected mild cognitive impairment (i.e., T-score < 40 in at least one cognitive domain) in 60% of heart failure patients. pTau (p = 0.014), but not NfL, was elevated in this group. Both NfL (ρ = − 0.21; p = 0.013) and pTau (ρ = − 0.25; p = 0.002) related to the cognitive domain visual/verbal memory, as well as white matter hyperintensity volume and cerebral and hippocampal atrophy. In multivariable analysis, both biomarkers were independently influenced by age (T = 4.6 for pTau; T = 5.9 for NfL) and glomerular filtration rate (T = − 2.4 for pTau; T = − 3.4 for NfL). Markers of chronic heart failure, left atrial volume index (T = 4.6) and NT-proBNP (T = 2.8), were further cardiological determinants of pTau and NfL, respectively. In addition, pTau was also strongly affected by serum creatine kinase levels (T = 6.5) and ferritin (T = − 3.1). Conclusions pTau and NfL serum levels are strongly influenced by age-dependent renal and cardiac dysfunction. These findings point towards the need for longitudinal examinations and consideration of frequent comorbidities when using neuronal serum biomarkers. KW - Alzheimer’s dementia KW - heart failure KW - cognitive impairment KW - neurofilament light chain KW - phosphorylated tau protein KW - renal function KW - age Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-300515 VL - 14 ER - TY - JOUR A1 - Wiechmann, Tobias A1 - Röh, Simone A1 - Sauer, Susann A1 - Czamara, Darina A1 - Arloth, Janine A1 - Ködel, Maik A1 - Beintner, Madita A1 - Knop, Lisanne A1 - Menke, Andreas A1 - Binder, Elisabeth B. A1 - Provençal, Nadine T1 - Identification of dynamic glucocorticoid-induced methylation changes at the FKBP5 locus JF - Clinical Epigenetics N2 - Background Epigenetic mechanisms may play a major role in the biological embedding of early-life stress (ELS). One proposed mechanism is that glucocorticoid (GC) release following ELS exposure induces long-lasting alterations in DNA methylation (DNAm) of important regulatory genes of the stress response. Here, we investigate the dynamics of GC-dependent methylation changes in key regulatory regions of the FKBP5 locus in which ELS-associated DNAm changes have been reported. Results We repeatedly measured DNAm in human peripheral blood samples from 2 independent cohorts exposed to the GC agonist dexamethasone (DEX) using a targeted bisulfite sequencing approach, complemented by data from Illumina 450K arrays. We detected differentially methylated CpGs in enhancers co-localizing with GC receptor binding sites after acute DEX treatment (1 h, 3 h, 6 h), which returned to baseline levels within 23 h. These changes withstood correction for immune cell count differences. While we observed main effects of sex, age, body mass index, smoking, and depression symptoms on FKBP5 methylation levels, only the functional FKBP5 SNP (rs1360780) moderated the dynamic changes following DEX. This genotype effect was observed in both cohorts and included sites previously shown to be associated with ELS. Conclusion Our study highlights that DNAm levels within regulatory regions of the FKBP5 locus show dynamic changes following a GC challenge and suggest that factors influencing the dynamics of this regulation may contribute to the previously reported alterations in DNAm associated with current and past ELS exposure. KW - DNA methylation KW - FKBP5 KW - glucocorticoid receptor KW - early-life stress KW - targeted bisulfite sequencing KW - dexamethasone Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-233673 VL - 11 ER -